Bocchia M et al. (2005) Effect of a p210 multipeptide vaccine associated with imatinib or interferon in patients with chronic myeloid leukaemia and persistent residual disease: a multicentre observational trial. Lancet 365: 657–662
Early results from an observational trial in Italy suggest that a new vaccine might improve outcomes in patients with chronic myeloid leukemia.
The multipeptide vaccine, named CMLVAX100, was designed to target the b3a2 splice-region variant of the BCR-ABL-derived fusion protein p210, expression of which is specific to chronic myeloid leukemia. Sixteen patients with persistent, stable, b3a2-related chronic myeloid leukemia each received six subcutaneous vaccinations every 2 weeks. All patients continued to receive conventional treatment with imatinib or interferon-alpha (IFN-α).
The vaccine was well tolerated and appeared to generate an antitumor effect in the majority of patients. After 3 months, improved cytogenetic responses were observed in all nine imatinib-treated patients who had cytogenetic disease at baseline, and in five of the six patients receiving IFN-α. A total of seven patients achieved complete cytogenetic remission. Furthermore, a molecular response—indicated by a failure to detect BCR-ABL transcripts—was observed in four of these patients. The one imatinib-treated patient who began the study in complete cytogenetic remission also showed a reduction in residual molecular disease after receiving the vaccine.
The investigators conclude that vaccination with CMLVAX100 might help to reduce residual disease in patients with b3a2-related chronic myeloid leukemia, and might also improve molecular response rates. The results of larger studies are awaited.
Rights and permissions
About this article
Cite this article
Advances in immunotherapy for chronic myeloid leukemia. Nat Rev Clin Oncol 2, 174 (2005). https://doi.org/10.1038/ncponc0144
Issue Date:
DOI: https://doi.org/10.1038/ncponc0144